Compare MakeMyTrip Ltd (MMYT) vs TG Therapeutics Inc (TGTX) Price & Performance

MMYT trades at $60.31, down 1.79% today, with a bullish technical signal from moving averages and a strong buy consensus from analysts (8 buy, 3 hold). Recent Q1 2027 earnings beat expectations despite revenue softness, driven by growth in hotels and packages. The company maintains solid liquidity with $761.18M cash and a gross margin of 73.45%, though net income margin is modest at 3.23%.

Outlook is positive with analyst targets suggesting 34.12% upside, but risks include geopolitical disruptions impacting travel, elevated P/E of 262.35, and a projected decline in 2026 net cash flow. The stock's valuation relies on sustained earnings growth and recovery in air-ticketing segments.

TG Therapeutics (TGTX) trades at $49.50, down 0.8% with a bearish technical signal. The company reported strong revenue growth with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though earnings have missed expectations for three consecutive quarters. Analyst consensus remains bullish with 84.6% buy ratings and a $63.75 price target, representing 29% upside potential from current levels.

The outlook is mixed with strong revenue momentum from BRIUMVI offset by earnings misses and negative cash flow. Key risks include ongoing earnings underperformance, shareholder litigation, and high valuation multiples. The stock offers growth potential but requires careful monitoring of execution and profitability trends.